Pardoll Drew, Allison James
Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Nat Med. 2004 Sep;10(9):887-92. doi: 10.1038/nm0904-887.
Successful translation of modern molecular immunology into effective cancer immunotherapy is threatened by regulatory barriers and challenges to the development of novel agents and combinatorial strategies through effective public-private partnerships. For its promise to be fully realized, both the National Cancer Institute and Food and Drug Administration must take active steps to help academic investigators and companies jointly navigate the pathways from laboratory to clinic.
现代分子免疫学成功转化为有效的癌症免疫疗法受到监管障碍以及通过有效的公私合作开发新型药物和联合策略所面临挑战的威胁。为了充分实现其前景，美国国立癌症研究所和食品药品监督管理局都必须采取积极措施，帮助学术研究人员和公司共同探索从实验室到临床的路径。
